Affimed to Host Investor Conference Call Highlighting Clinical Data from AFM24 in Combination with Atezolizumab in Non-Small Cell Lung Cancer
Affimed N.V. (Nasdaq: AFMD) announced it will host a conference call on Tuesday, December 17, at 8:30 a.m. EST / 14:30 CET to review clinical data from AFM24-102, a combination trial of its AFM24 innate cell engager ICE® with atezolizumab in non-small cell lung cancer. The call will be accessible via phone and webcast through the company's website, with dial-in details provided upon registration. A replay will be available for 30 days following the call.
Affimed N.V. (Nasdaq: AFMD) ha annunciato che ospiterà una conferenza telefonica martedì 17 dicembre alle 8:30 EST / 14:30 CET per rivedere i dati clinici dell'AFM24-102, uno studio combinato del suo engager di cellule innate ICE® AFM24 con atezolizumab nel carcinoma polmonare non a piccole cellule. La chiamata sarà accessibile tramite telefono e webcast attraverso il sito web dell'azienda, con i dettagli per il collegamento forniti al momento della registrazione. Una registrazione sarà disponibile per 30 giorni dopo la chiamata.
Affimed N.V. (Nasdaq: AFMD) anunció que llevará a cabo una conferencia telefónica el martes 17 de diciembre a las 8:30 a.m. EST / 14:30 CET para revisar datos clínicos de AFM24-102, un ensayo combinado de su enganchador de células innatas ICE® AFM24 con atezolizumab en cáncer de pulmón no microcítico. La llamada será accesible por teléfono y por webcast a través del sitio web de la compañía, con detalles de acceso proporcionados al registrarse. Una grabación estará disponible durante 30 días después de la llamada.
Affimed N.V. (Nasdaq: AFMD)는 12월 17일 화요일 오전 8시 30분 EST / 오후 2시 30분 CET에 AFM24-102의 임상 데이터를 검토하기 위해 컨퍼런스 콜을 개최한다고 발표했습니다. 이 연구는 자사의 AFM24 천연 세포 인게이저 ICE®와 아테졸리주맙의 조합 시험입니다. 전화와 웹캐스트를 통해 회사 웹사이트에서 통화에 접속할 수 있으며, 등록 시 접속 세부정보가 제공됩니다. 통화 후 30일 동안 재생 가능합니다.
Affimed N.V. (Nasdaq: AFMD) a annoncé qu'elle organisera une conférence téléphonique le mardi 17 décembre à 8h30 EST / 14h30 CET pour examiner les données cliniques de l'AFM24-102, un essai combiné de son engageur de cellules innées ICE® AFM24 avec l'atezolizumab dans le cadre du cancer du poumon non à petites cellules. L'appel sera accessible par téléphone et par webdiffusion via le site Web de l'entreprise, les détails d'appel étant fournis lors de l'enregistrement. Un enregistrement sera disponible pendant 30 jours après l'appel.
Affimed N.V. (Nasdaq: AFMD) hat bekannt gegeben, dass am Dienstag, den 17. Dezember um 8:30 Uhr EST / 14:30 Uhr CET eine Telefonkonferenz stattfinden wird, um klinische Daten zu AFM24-102, einer Kombinationsstudie mit dem angeborenen Zellengager ICE® AFM24 und Atezolizumab bei nicht-kleinzelligem Lungenkrebs, zu überprüfen. Der Anruf wird sowohl telefonisch als auch per Webcast über die Website des Unternehmens zugänglich sein, wobei die Einwahldaten bei der Anmeldung bereitgestellt werden. Eine Aufzeichnung wird 30 Tage nach dem Anruf verfügbar sein.
- None.
- None.
MANNHEIM, Germany, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will host a conference call on Tuesday, December 17, at 8:30 a.m. EST / 14:30 CET to review clinical data from AFM24-102, the combination trial of its AFM24 innate cell engager ICE® with atezolizumab in non-small cell lung cancer.
The conference call will be available via phone and webcast. The live audio webcast of the call will be available in the “Webcasts” section on the “Investors” page of the Affimed website at https://www.affimed.com/investors/webcasts-and-corporate-presentation/. To access the call by phone, please use link
https://register.vevent.com/register/BI9c2d6fa7af764cb7b550c5ce464ce5cf, and you will be provided with dial-in details and a pin number.
Note: To avoid delays, we encourage participants to dial into the conference call 15 minutes ahead of the scheduled start time. A replay of the webcast will be accessible at the same link for 30 days following the call.
About Affimed N.V.
Affimed (Nasdaq: AFMD) is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The Company’s innate cell engagers (ICE®) enable a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors. ICE® are generated on the Company’s proprietary ROCK® platform which predictably generates customized molecules that leverage the power of innate immune cells to destroy tumor cells. A number of ICE® molecules are in clinical development, being studied as mono- or combination therapy. Headquartered in Mannheim, Germany, Affimed is led by an experienced team of biotechnology and pharmaceutical leaders united by the bold vision to stop cancer from ever derailing patients’ lives. For more about the Company’s people, pipeline and partners, please visit: www.affimed.com.
Investor Relations Contact
Alexander Fudukidis
Director, Head of Investor Relations
E-Mail: a.fudukidis@affimed.com
Tel.: +1 (917) 436-8102
FAQ
When will Affimed (AFMD) present AFM24-102 clinical data for non-small cell lung cancer?
What is the focus of Affimed's AFM24-102 trial?
How can investors access Affimed's AFM24-102 clinical data presentation?
